Revenue | $10 - $100 million See Exact Annual Revenue |
---|---|
Employees | N/AExact Company Size |
Primary Industry | 3254 Pharmaceutical & Medicine Manufacturing |
Address | 124 Washington St Ste 101 Foxborough, MA 02035 |
Kaleido Biosciences | Revenue Est. ($ Million) | Growth Rate (%) | # Employees |
---|---|---|---|
2023 | Details in Premium Report | ||
2022 | |||
2021 | |||
2020 | |||
2019 |
1-Year Growth Rate: 3-Year Growth Rate (CAGR): |
$ Millions (Industry Average) | |
---|---|
Kaleido Biosciences Revenue (Sales) | |
Cost of Goods Sold | |
Gross Profit | |
Operating Expenses | |
Advertising | |
Salaries and wages | |
Other Operating Expenses | |
Total Operating Expenses | |
Operating Income | |
EBITDA | |
EBIT (Earnings Before Interest and Taxes) | |
Net Profit | |
Trademark | Date |
---|---|
MICROBIOME ENHANCER Therapeutic pharmaceuticals for medical use for influencing microbiome imbalances, and treatment of dysbiosis and gastro-intestinal diseases in humans; dietetic foods and beverages adapted for medical use; dietary supplements; nutritional supplements; nutraceuticals for influencing and treating microbiome imbalances; hygiene products, namely, medicated body wash; drug testing kits comprised of diagnostic reagents and assays for testing body excretions; diagnostic reagents for medical use | 10/06/2016 |
KALEIDO preparations and substances for pharmaceutical and medical purposes, namely, for the treatment of dysbioses, inflammatory disorders and conditions, infectious diseases, metabolic diseases, nutritional disorders, malnutrition, immune-mediated diseases, including autoimmune diseases, allergies, and immune tolerance, malignancies and cancers, neurological diseases, psychiatric conditions, gastrointestinal diseases and disorders, gastrointestinal injury conditions, digestive abnormalities, dermatological conditions, cardiovascular diseases, nephrologic diseases and conditions, including organ failure, ophthalmic disorders, vaginal and penile conditions, pediatric disorders and conditions, including growth and developmental conditions, and geriatric disorders and conditions, all of the foregoing related to the microbiome and all of the foregoing excluding treatments for cystic fibrosis; therapeutic pharmaceuticals for medical use, namely, for the treatment of dysbioses, inflammatory disorders and conditions, infectious diseases, metabolic diseases, nutritional disorders, malnutrition, immune-mediated diseases, including autoimmune diseases, allergies, and immune tolerance, malignancies and cancers, neurological diseases, psychiatric conditions, gastrointestinal diseases and disorders, gastrointestinal injury conditions, digestive abnormalities, dermatological conditions, cardiovascular diseases, nephrologic diseases and conditions, including organ failure, ophthalmic disorders, vaginal and penile conditions, pediatric disorders and conditions, including growth and developmental conditions, and geriatric disorders and conditions, all of the foregoing related to the microbiome and all of the foregoing excluding treatments for cystic fibrosis | 10/09/2015 |
Publisher: AnythingResearch
Company | Headquarters | Revenue ($ MM) |
---|---|---|
PFIZER | New York, NY | 100 |
ABBOTT LABORATORIES | Abbott Park, IL | 91 |
BRISTOL-MYERS SQUIBB | Princeton, NJ | 86 |
MERCK SHARP & DOHME | Rahway, NJ | 66 |
ELI LILLY | Indianapolis, IN | 65 |
CSL BEHRING | King Of Prussia, PA | 64 |
CSLB HOLDINGS | King Of Prussia, PA | 63 |
MERCK | Rahway, NJ | 62 |
ALLERGAN | Chicago, IL | 61 |
Company | Headquarters | Revenue ($ MM) |
---|---|---|
RUBIUS THERAPEUTICS | Foxborough, MA | 100 |
KALEIDO BIOSCIENCES | Foxborough, MA | 21 |
APTINYX | Foxborough, MA | 8 |
CORBUS PHARMACEUTICALS | Norwood, MA | 7 |
KINASET THERAPEUTICS | Medfield, MA | 0 |
Company | Revenue ($ MM) |
---|---|
|